STING nanovaccine

**STING nanovaccine** is an investigational, intravenously administered therapeutic nanoparticle vaccine developed at UT Southwestern Medical Center for HPV-induced cancers. The approximately 25–30 nm dual-stimuli-responsive nanoparticle co-delivers human papillomavirus type 16 E7 protein antigen with a diABZI small-molecule STING agonist conjugated to the STING-activating polymer PSC7A through an azobenzene linker. Acidic pH and myeloid-cell NQO1 activity promote payload activation, enabling STING-mediated innate immune activation and E7-specific CD8-positive T-cell priming while reducing systemic toxicity. It produced antitumor activity in mouse models of primary and metastatic HPV16-associated tumors and remains a preclinical program. ([pnas.org](https://www.pnas.org/doi/pdf/10.1073/pnas.2409570122))

Other names

Dual-stimuli-responsive STING nanovaccineSTING nanovaccineStimuli-responsive STING nanovaccine